BioNTech Investor Presentation Deck

Advancing Toward Our Vision 1 marketed vaccine Market leader in COVID-19 vaccines 18 programs in 23 clinical trials 5 randomized Phase 2 trials 16 Oncology 1 Phase 1 program 10+ preclinical programs, 4 FIH trials to start Infectious diseases Driving transformation today Next-gen or variant adapted COVID-19 vaccines Multiple product launches in next 3-5 yrs 5-10 IND submissions per year Mid-term goals Once in a generation opportunity to transform medicine Maintain and deepen COVID-19 vaccine leadership Approved products across various disease areas Expand to new disease areas: autoimmune disease, regenerative medicine, cardiovascular diseases Long-term vision BIONTECH

View entire presentation